Clinical Trial MilestoneInventiva has completed enrollment of the NATiV3 trial, setting the stage for a definitive topline readout and meeting the requirements to access the second tranche of financing.
Financial StabilityThe company's previous funding concerns were resolved with a significant financing, making it an appealing asset with blockbuster potential.
Market PotentialLanifibranor could become the second orally-dosed MASH therapy approved by the FDA, exhibiting a stronger efficacy profile compared to resmetirom.
Strategic PartnershipsThe Phase III NATiV3 trial for lanifibranor has completed full enrollment and is on track to report Phase III top-line data, making it a compelling asset for partnering.